Colitis refers to inflammation of the colon and may be caused by infections, inflammatory bowel disease, ischemia, medications, or other conditions.
Lyell Immunopharma initiated the Phase 3 PiNACLE–H2H trial of ronde-cel in large B-cell lymphoma and reported that GI prophylaxis reduced severe diarrhea rates from 55% to 10% in the Phase 1 LYL273 trial.
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
Immune checkpoint inhibitors are associated with a significantly lower risk of non-neovascular age-related macular degeneration, while sociodemographic disparities strongly influence diabetic retinopathy screening adherence, according to two separate ophthalmology studies.
Dual immunotherapy allowed 70.6% of MSI-H gastric cancer patients to avoid surgery in the INFINITY trial. German off-label immunotherapy shows 20-25% response rates, requiring careful patient selection.
Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.
Cabozantinib plus metronomic temozolomide showed a 15% response rate and 28.5-month median progression-free survival in a phase 2 NET study. A separate analysis found cabozantinib cost-effective for pancreatic NETs, but not extrapancreatic NETs, in China and the U.S.
Researchers used machine learning to identify an antimicrobial peptide, LR, that reduced inflammation and improved gut barrier function in mouse ulcerative colitis. The peptide also reshaped the microbiome and outperformed 5-aminosalicylic acid and ciprofloxacin in the model.
Meta-analysis of 23 trials finds neoadjuvant chemoimmunotherapy achieved 66% major pathologic response in head and neck cancer patients compared to 18% for dual-agent and 6% for single-agent immunotherapy, though survival impact remains unclear.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07652294 |
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07619898 |
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure |
NOT_YET_RECRUITING | PHASE2 |
| NCT07619638 |
AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis |
RECRUITING | NA |
| NCT07541261 |
A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia |
RECRUITING | |
| NCT07196410 |
KAN-004 for Immune-Related Diarrhea or Colitis |
RECRUITING | PHASE1 |
| NCT07047339 |
Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis |
RECRUITING | PHASE2/PHASE3 |
| NCT07012395 |
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis |
RECRUITING | PHASE2 |
| NCT06424769 |
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management |
ENROLLING_BY_INVITATION | NA |
| NCT06223347 |
Improved and Simplified Staining Technique for Dysplasia Detection in Colitis |
RECRUITING | |
| NCT06206707 |
FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis |
RECRUITING | NA |
